0.00
100.00%
-31.23
Immunogen, Inc. 주식(IMGN)의 최신 뉴스
Immunogen (IMGN) Price Target Increased by 6.47% to 24.25 - MSN
MSN
An Intrinsic Calculation For ImmunoGen, Inc. (NASDAQ:IMGN) Suggests It's 47% Undervalued - Yahoo New Zealand News
Yahoo New Zealand News
Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now - Yahoo New Zealand News
Yahoo New Zealand News
ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Singapore News
Yahoo Singapore News
ImmunoGen (IMGN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Movies UK
Yahoo Movies UK
ImmunoGen (IMGN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Singapore News
Yahoo Singapore News
ImmunoGen, Inc. Announces FDA Approval of Kadcyla (Ado-Trastuzumab Emtansine; Also Known as T-DM1) - Yahoo Movies Canada
Yahoo Movies Canada
Rainbows and Unicorns: ImmunoGen, Inc. (NASDAQ:IMGN) Analysts Just Became A Lot More Optimistic - Yahoo Movies UK
Yahoo Movies UK
AbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen Deal - MarketWatch
MarketWatch
AbbVie Sells $15 Billion of Bonds to Buy ImmunoGen, Cerevel - Bloomberg
Bloomberg
AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A - Bloomberg
Bloomberg
Pharmaceutical Technology - Pharmaceutical Technology
Pharmaceutical Technology
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
Zacks Investment Research
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
Zacks Investment Research
ImmunoGen Finalizes Merger, Amends Operations, and Delists Shares - TipRanks.com - TipRanks
TipRanks
AbbVie Completes ImmunoGen Acquisition Amidst Cautious Outlook - TipRanks.com - TipRanks
TipRanks
AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen - MarketWatch
MarketWatch
Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication
Zacks Investment Research
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
Zacks Investment Research
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
Zacks Investment Research
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Yahoo Finance
Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted
Zacks Investment Research
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
Zacks Investment Research
REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up
Zacks Investment Research
Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat
Zacks Investment Research
Immunogen leads as BCI's top performer in 2023 as index ends year up 76% - BioWorld Online
BioWorld Online
AbbVie’s fourth-quarter sales top estimates despite plunging Humira revenues
MarketWatch
Immunogen Shareholders Approve Merger with AbbVie Inc. - TipRanks.com - TipRanks
TipRanks
Immunogen Shareholders Approve Merger with AbbVie Inc. - TipRanks.com - TipRanks
TipRanks
ImmunoGen's Merger with AbbVie Awaits Shareholder Approval - TipRanks.com - TipRanks
TipRanks
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
Benzinga
Should First Trust Mid Cap Core AlphaDEX ETF (FNX) Be on Your Investing Radar?
Zacks Investment Research
Immunogen Merges with AbbVie, Responds to Shareholder Complaints - TipRanks.com - TipRanks
TipRanks
Is First Trust Mid Cap Core AlphaDEX ETF (FNX) a Strong ETF Right Now?
Zacks Investment Research
ImmunoGen Sued Over Alleged Omissions in AbbVie Buyout Proxy - Bloomberg Law
Bloomberg Law
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
Zacks Investment Research
Should JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC) Be on Your Investing Radar?
Zacks Investment Research
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry
Zacks Investment Research
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry - Yahoo Finance
Yahoo Finance
Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'
Benzinga
ImmunoGen Undervalued In AbbVie Deal, Shareholder Claims - Law360
Law360
Is AbbVie Stock a Buy Now?
The Motley Fool
All AbbVie's CEO wanted for Christmas was Cerevel—oh, and ImmunoGen, too - Fierce Biotech
Fierce Biotech
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy
Zacks Investment Research
New Strong Buy Stocks for January 4th - MSN
MSN
New Strong Buy Stocks for January 4th
Zacks Investment Research
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy - Yahoo Finance
Yahoo Finance
Inside AbbVie's $10B buyout of ImmunoGen—and the bidding war it swooped in on - FiercePharma
FiercePharma
Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
자본화:
|
볼륨(24시간):